GS,
I agree 100% that we either need more progress publicized by Abbott or a new licensee. Those two things will validate our product. Anything else from the company or a paid PR firm will do little for the stock price, IMO.
I have been really frustrated with the pullback in stock price since the ISOBM news. I expect that the company hoped to follow ISOBM more closely with news of a licensee. Well, it hasn't worked out yet and we still wait. Some are tired of waiting like Zolax. While I am frustrated, I remember messages from years ago expressing the same frustration waiting for the first licensee. The Abbott deal finally came through and I think a second deal will also.
I also remember a message that listed milestones that were finally achieved by Dr. Moro after longer than expected waits. One was the Abbott deal, another was getting the stock off the Pink Sheets. I can't remember the others, but the company has eventually done what they said they were going to do.
I think we should make a new list of expected milestones worth waiting for: a second licensee, beginning clinical trials, Abbott feasibility milestone, etc. I still think these things will happen eventually, so I will keep waiting.
